Mucosal melanoma

INTRODUCTION

Melanomas may arise from the mucosal epithelium lining the respiratory, alimentary, and genitourinary tracts, all of which contain melanocytes, as well as from the skin.

Mucosal melanomas generally carry a worse prognosis than those arising from cutaneous sites. Because of the rarity of mucosal melanoma, and because of the unique biology and clinical challenges of mucosal melanoma arising from each anatomic location, our understanding of these malignancies and their optimal management remains limited.

General aspects of mucosal melanoma, as well as the specific approach to patients with mucosal melanomas arising in the head and neck, vulvovaginal, and anorectal regions, are discussed here.

MUCOSAL VERSUS CUTANEOUS MELANOMA

There are substantial differences in mucosal as opposed to cutaneous melanomas that have important implications for patient management.

Epidemiology — Mucosal melanomas are rare and account for approximately 1 percent of all melanomas [1]. Mucosal melanomas arise primarily in the head and neck, anorectal, and vulvovaginal regions (55, 24, and 18 percent of cases, respectively). Rarer sites of origin include the urinary tract, gall bladder, and small intestine.

                                     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Jul 10, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83:1664.
  2. Meleti M, Leemans CR, de Bree R, et al. Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck 2008; 30:1543.
  3. Rapini RP, Golitz LE, Greer RO Jr, et al. Primary malignant melanoma of the oral cavity. A review of 177 cases. Cancer 1985; 55:1543.
  4. Sutherland CM, Chmiel JS, Henson DE, Winchester DP. Patient characteristics, methods of diagnosis, and treatment of mucous membrane melanoma in the United States of America. J Am Coll Surg 1994; 179:561.
  5. Pandey M, Mathew A, Abraham EK, et al. Primary malignant melanoma of the mucous membranes. Eur J Surg Oncol 1998; 24:303.
  6. Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol 2007; 56:828.
  7. McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer 2005; 103:1000.
  8. Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of california cancer registry data, 1988-93. Cancer Causes Control 1997; 8:246.
  9. Lotem M, Anteby S, Peretz T, et al. Mucosal melanoma of the female genital tract is a multifocal disorder. Gynecol Oncol 2003; 88:45.
  10. Carvajal RD, Spencer SA, Lydiatt W. Mucosal melanoma: a clinically and biologically unique disease entity. J Natl Compr Canc Netw 2012; 10:345.
  11. Ballantyne AJ. Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. Am J Surg 1970; 120:425.
  12. Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer 1997; 80:1373.
  13. Nandapalan V, Roland NJ, Helliwell TR, et al. Mucosal melanoma of the head and neck. Clin Otolaryngol Allied Sci 1998; 23:107.
  14. Patel SG, Prasad ML, Escrig M, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck 2002; 24:247.
  15. McLean N, Tighiouart M, Muller S. Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma. Oral Oncol 2008; 44:1039.
  16. DeMatos P, Tyler DS, Seigler HF. Malignant melanoma of the mucous membranes: a review of 119 cases. Ann Surg Oncol 1998; 5:733.
  17. Bachar G, Loh KS, O'Sullivan B, et al. Mucosal melanomas of the head and neck: experience of the Princess Margaret Hospital. Head Neck 2008; 30:1325.
  18. Johnson IJ, Warfield AT, Smallman LA, Watkinson JC. Primary malignant melanoma of the pharynx. J Laryngol Otol 1994; 108:275.
  19. Amin HH, Petruzzelli GJ, Husain AN, Nickoloff BJ. Primary malignant melanoma of the larynx. Arch Pathol Lab Med 2001; 125:271.
  20. Archer HA, Owen WJ. Primary malignant melanoma of the esophagus. Dis Esophagus 2000; 13:320.
  21. Ahn JY, Hwang HS, Park YS, et al. Endoscopic and pathologic findings associated with clinical outcomes of melanoma in the upper gastrointestinal tract. Ann Surg Oncol 2014; 21:2532.
  22. Stern SJ, Guillamondegui OM. Mucosal melanoma of the head and neck. Head Neck 1991; 13:22.
  23. Lee SP, Shimizu KT, Tran LM, et al. Mucosal melanoma of the head and neck: the impact of local control on survival. Laryngoscope 1994; 104:121.
  24. Moreno MA, Roberts DB, Kupferman ME, et al. Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center. Cancer 2010; 116:2215.
  25. Mucosal melanoma of the Head and Neck. In: AJCC Cancer Staging Manual, Seventh, Springer, 2010. p.97.
  26. Prasad ML, Patel SG, Huvos AG, et al. Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors. Cancer 2004; 100:1657.
  27. Thompson LD, Wieneke JA, Miettinen M. Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol 2003; 27:594.
  28. Ganly I, Patel SG, Singh B, et al. Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study. Arch Otolaryngol Head Neck Surg 2006; 132:73.
  29. Lund VJ, Howard DJ, Harding L, Wei WI. Management options and survival in malignant melanoma of the sinonasal mucosa. Laryngoscope 1999; 109:208.
  30. Hanna E, DeMonte F, Ibrahim S, et al. Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg 2009; 135:1219.
  31. Panje WR, Moran WJ. Melanoma of the upper aerodigestive tract: a review of 21 cases. Head Neck Surg 1986; 8:309.
  32. Krengli M, Masini L, Kaanders JH, et al. Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2006; 65:751.
  33. Loree TR, Mullins AP, Spellman J, et al. Head and neck mucosal melanoma: a 32-year review. Ear Nose Throat J 1999; 78:372.
  34. Medina JE, Ferlito A, Pellitteri PK, et al. Current management of mucosal melanoma of the head and neck. J Surg Oncol 2003; 83:116.
  35. Stárek I, Koranda P, Benes P. Sentinel lymph node biopsy: A new perspective in head and neck mucosal melanoma? Melanoma Res 2006; 16:423.
  36. Baptista P, Garcia Velloso MJ, Salvinelli F, Casale M. Radioguided surgical strategy in mucosal melanoma of the nasal cavity. Clin Nucl Med 2008; 33:14.
  37. Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg 2003; 129:864.
  38. Nakashima JP, Viégas CM, Fassizoli AL, et al. Postoperative adjuvant radiation therapy in the treatment of primary head and neck mucosal melanomas. ORL J Otorhinolaryngol Relat Spec 2008; 70:344.
  39. Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer 2005; 103:313.
  40. Yii NW, Eisen T, Nicolson M, et al. Mucosal malignant melanoma of the head and neck: the Marsden experience over half a century. Clin Oncol (R Coll Radiol) 2003; 15:199.
  41. Benlyazid A, Thariat J, Temam S, et al. Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study. Arch Otolaryngol Head Neck Surg 2010; 136:1219.
  42. Wu AJ, Gomez J, Zhung JE, et al. Radiotherapy after surgical resection for head and neck mucosal melanoma. Am J Clin Oncol 2010; 33:281.
  43. Yanagi T, Mizoe JE, Hasegawa A, et al. Mucosal malignant melanoma of the head and neck treated by carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2009; 74:15.
  44. Wada H, Nemoto K, Ogawa Y, et al. A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan. Int J Radiat Oncol Biol Phys 2004; 59:495.
  45. Cheng YF, Lai CC, Ho CY, et al. Toward a better understanding of sinonasal mucosal melanoma: clinical review of 23 cases. J Chin Med Assoc 2007; 70:24.
  46. Dauer EH, Lewis JE, Rohlinger AL, et al. Sinonasal melanoma: a clinicopathologic review of 61 cases. Otolaryngol Head Neck Surg 2008; 138:347.
  47. Katz EE, Suzue K, Wille MA, et al. Primary malignant melanoma of the urethra. Urology 2005; 65:389.
  48. Kojima T, Tanaka T, Yoshimi N, Mori H. Primary malignant melanoma of the urinary bladder. Arch Pathol Lab Med 1992; 116:1213.
  49. Khalbuss WE, Hossain M, Elhosseiny A. Primary malignant melanoma of the urinary bladder diagnosed by urine cytology: a case report. Acta Cytol 2001; 45:631.
  50. Clark KC, Butz WR, Hapke MR. Primary malignant melanoma of the uterine cervix: case report with world literature review. Int J Gynecol Pathol 1999; 18:265.
  51. Cantuaria G, Angioli R, Nahmias J, et al. Primary malignant melanoma of the uterine cervix: case report and review of the literature. Gynecol Oncol 1999; 75:170.
  52. Creasman WT, Phillips JL, Menck HR. A survey of hospital management practices for vulvar melanoma. J Am Coll Surg 1999; 188:670.
  53. Stang A, Streller B, Eisinger B, Jöckel KH. Population-based incidence rates of malignant melanoma of the vulva in Germany. Gynecol Oncol 2005; 96:216.
  54. Ragnarsson-Olding BK, Kanter-Lewensohn LR, Lagerlöf B, et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: clinical observations and histopathologic features. Cancer 1999; 86:1273.
  55. Wechter ME, Gruber SB, Haefner HK, et al. Vulvar melanoma: a report of 20 cases and review of the literature. J Am Acad Dermatol 2004; 50:554.
  56. Piura B, Egan M, Lopes A, Monaghan JM. Malignant melanoma of the vulva: a clinicopathologic study of 18 cases. J Surg Oncol 1992; 50:234.
  57. Piura B, Rabinovich A, Dgani R. Malignant melanoma of the vulva: report of six cases and review of the literature. Eur J Gynaecol Oncol 1999; 20:182.
  58. Verschraegen CF, Benjapibal M, Supakarapongkul W, et al. Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later. Int J Gynecol Cancer 2001; 11:359.
  59. Piura B, Rabinovich A, Yanai-Inbar I. Primary malignant melanoma of the vagina: case report and review of literature. Eur J Gynaecol Oncol 2002; 23:195.
  60. Sugiyama VE, Chan JK, Shin JY, et al. Vulvar melanoma: a multivariable analysis of 644 patients. Obstet Gynecol 2007; 110:296.
  61. Borazjani G, Prem KA, Okagaki T, et al. Primary malignant melanoma of the vagina: a clinicopathological analysis of 10 cases. Gynecol Oncol 1990; 37:264.
  62. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635.
  63. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29:705.
  64. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902.
  65. Chung AF, Woodruff JM, Lewis JL Jr. Malignant melanoma of the vulva: A report of 44 cases. Obstet Gynecol 1975; 45:638.
  66. Phillips GL, Bundy BN, Okagaki T, et al. Malignant melanoma of the vulva treated by radical hemivulvectomy. A prospective study of the Gynecologic Oncology Group. Cancer 1994; 73:2626.
  67. Moxley KM, Fader AN, Rose PG, et al. Malignant melanoma of the vulva: an extension of cutaneous melanoma? Gynecol Oncol 2011; 122:612.
  68. Buchanan DJ, Schlaerth J, Kurosaki T. Primary vaginal melanoma: thirteen-year disease-free survival after wide local excision and review of recent literature. Am J Obstet Gynecol 1998; 178:1177.
  69. Petru E, Nagele F, Czerwenka K, et al. Primary malignant melanoma of the vagina: long-term remission following radiation therapy. Gynecol Oncol 1998; 70:23.
  70. Irvin WP Jr, Legallo RL, Stoler MH, et al. Vulvar melanoma: a retrospective analysis and literature review. Gynecol Oncol 2001; 83:457.
  71. Trimble EL. Melanomas of the vulva and vagina. Oncology (Williston Park) 1996; 10:1017.
  72. DeMatos P, Tyler D, Seigler HF. Mucosal melanoma of the female genitalia: a clinicopathologic study of forty-three cases at Duke University Medical Center. Surgery 1998; 124:38.
  73. Ragnarsson-Olding BK, Nilsson BR, Kanter-Lewensohn LR, et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival. Cancer 1999; 86:1285.
  74. Miner TJ, Delgado R, Zeisler J, et al. Primary vaginal melanoma: a critical analysis of therapy. Ann Surg Oncol 2004; 11:34.
  75. Suwandinata FS, Bohle RM, Omwandho CA, et al. Management of vulvar melanoma and review of the literature. Eur J Gynaecol Oncol 2007; 28:220.
  76. Bradgate MG, Rollason TP, McConkey CC, Powell J. Malignant melanoma of the vulva: a clinicopathological study of 50 women. Br J Obstet Gynaecol 1990; 97:124.
  77. Trimble EL, Lewis JL Jr, Williams LL, et al. Management of vulvar melanoma. Gynecol Oncol 1992; 45:254.
  78. Irvin WP Jr, Bliss SA, Rice LW, et al. Malignant melanoma of the vagina and locoregional control: radical surgery revisited. Gynecol Oncol 1998; 71:476.
  79. de Hullu JA, Hollema H, Hoekstra HJ, et al. Vulvar melanoma: is there a role for sentinel lymph node biopsy? Cancer 2002; 94:486.
  80. Dhar KK, DAS N, Brinkman DA, et al. Utility of sentinel node biopsy in vulvar and vaginal melanoma: report of two cases and review of the literature. Int J Gynecol Cancer 2007; 17:720.
  81. Jaramillo BA, Ganjei P, Averette HE, et al. Malignant melanoma of the vulva. Obstet Gynecol 1985; 66:398.
  82. Gökaslan H, Sişmanoğlu A, Pekin T, et al. Primary malignant melanoma of the vagina: a case report and review of the current treatment options. Eur J Obstet Gynecol Reprod Biol 2005; 121:243.
  83. Bonner JA, Perez-Tamayo C, Reid GC, et al. The management of vaginal melanoma. Cancer 1988; 62:2066.
  84. Weinstock MA. Malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival. Am J Obstet Gynecol 1994; 171:1225.
  85. Creasman WT, Phillips JL, Menck HR. The National Cancer Data Base report on cancer of the vagina. Cancer 1998; 83:1033.
  86. Frumovitz M, Etchepareborda M, Sun CC, et al. Primary malignant melanoma of the vagina. Obstet Gynecol 2010; 116:1358.
  87. Cagir B, Whiteford MH, Topham A, et al. Changing epidemiology of anorectal melanoma. Dis Colon Rectum 1999; 42:1203.
  88. Coté TR, Sobin LH. Primary melanomas of the esophagus and anorectum: epidemiologic comparison with melanoma of the skin. Melanoma Res 2009; 19:58.
  89. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104:1505.
  90. Bello DM, Smyth E, Perez D, et al. Anal versus rectal melanoma: does site of origin predict outcome? Dis Colon Rectum 2013; 56:150.
  91. Iddings DM, Fleisig AJ, Chen SL, et al. Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? Ann Surg Oncol 2010; 17:40.
  92. Pessaux P, Pocard M, Elias D, et al. Surgical management of primary anorectal melanoma. Br J Surg 2004; 91:1183.
  93. Cooper PH, Mills SE, Allen MS Jr. Malignant melanoma of the anus: report of 12 patients and analysis of 255 additional cases. Dis Colon Rectum 1982; 25:693.
  94. Weinstock MA. Epidemiology and prognosis of anorectal melanoma. Gastroenterology 1993; 104:174.
  95. Goldman S, Glimelius B, Påhlman L. Anorectal malignant melanoma in Sweden. Report of 49 patients. Dis Colon Rectum 1990; 33:874.
  96. Ross M, Pezzi C, Pezzi T, et al. Patterns of failure in anorectal melanoma. A guide to surgical therapy. Arch Surg 1990; 125:313.
  97. Roumen RM. Anorectal melanoma in The Netherlands: a report of 63 patients. Eur J Surg Oncol 1996; 22:598.
  98. Kubo K, Fujiyoshi T, Yokoyama MM, et al. Lack of association of Borna disease virus and human T-cell leukemia virus type 1 infections with psychiatric disorders among Japanese patients. Clin Diagn Lab Immunol 1997; 4:189.
  99. Brady MS, Kavolius JP, Quan SH. Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center. Dis Colon Rectum 1995; 38:146.
  100. Yeh JJ, Shia J, Hwu WJ, et al. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg 2006; 244:1012.
  101. Ballo MT, Gershenwald JE, Zagars GK, et al. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol 2002; 20:4555.
  102. Nilsson PJ, Ragnarsson-Olding BK. Importance of clear resection margins in anorectal malignant melanoma. Br J Surg 2010; 97:98.
  103. Droesch JT, Flum DR, Mann GN. Wide local excision or abdominoperineal resection as the initial treatment for anorectal melanoma? Am J Surg 2005; 189:446.
  104. Tien HY, McMasters KM, Edwards MJ, Chao C. Sentinel lymph node metastasis in anal melanoma: a case report. Int J Gastrointest Cancer 2002; 32:53.
  105. Perez DR, Trakarnsanga A, Shia J, et al. Locoregional lymphadenectomy in the surgical management of anorectal melanoma. Ann Surg Oncol 2013; 20:2339.
  106. Kelly P, Zagars GK, Cormier JN, et al. Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: A 20-year experience. Cancer 2011; 117:4747.
  107. Thibault C, Sagar P, Nivatvongs S, et al. Anorectal melanoma--an incurable disease? Dis Colon Rectum 1997; 40:661.
  108. Lian B, Si L, Cui C, et al. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res 2013; 19:4488.
  109. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305:2327.
  110. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24:4340.
  111. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005; 92:1398.
  112. Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006; 106:2005.
  113. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008; 99:734.
  114. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26:2046.
  115. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008; 21:492.
  116. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29:2904.
  117. Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013; 31:3182.
  118. Quintás-Cardama A, Lazar AJ, Woodman SE, et al. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008; 5:737.
  119. Woodman SE, Trent JC, Stemke-Hale K, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009; 8:2079.
  120. Zhu Y, Si L, Kong Y, et al. Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma. J Clin Oncol 2009; 27: (suppl: abstract e20017)
  121. Postow MA, Luke JJ, Bluth MJ, et al. Ipilimumab for patients with advanced mucosal melanoma. Oncologist 2013; 18:726.
  122. Del Vecchio M, Di Guardo L, Ascierto PA, et al. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 2014; 50:121.
  123. Kim KB, Sanguino AM, Hodges C, et al. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 2004; 100:1478.
  124. Harting MS, Kim KB. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. Melanoma Res 2004; 14:517.
  125. Bartell HL, Bedikian AY, Papadopoulos NE, et al. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 2008; 30:1592.
  126. Smyth EC, Flavin M, Pulitzer MP, et al. Treatment of locally recurrent mucosal melanoma with topical imiquimod. J Clin Oncol 2011; 29:e809.
  127. Hyde MA, Hadley ML, Tristani-Firouzi P, et al. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol 2012; 148:592.
  128. Bong AB, Bonnekoh B, Franke I, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002; 205:135.
  129. Wolf IH, Smolle J, Binder B, et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003; 139:273.
  130. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149 Suppl 66:66.
  131. Powell AM, Robson AM, Russell-Jones R, Barlow RJ. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol 2009; 160:994.